Baugher Amy R, Wejnert Cyprian, Kanny Dafna, Broz Dita, Feelemyer Jonathan, Hershow Rebecca B, Burnett Janet, Chapin-Bardales Johanna, Haynes Maya, Finlayson Teresa, Prejean Joseph
Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
AIDS. 2025 Oct 1;39(12):1813-1819. doi: 10.1097/QAD.0000000000004249. Epub 2025 Jun 4.
National HIV Behavioral Surveillance (NHBS) conducts surveillance among key populations, including persons who inject drugs (PWID). NHBS data can be used to monitor progress toward national goals, including Ending the HIV Epidemic (EHE). EHE strategies include HIV testing (Diagnose), rapid linkage to HIV treatment (Treat), and increasing access to preexposure prophylaxis (PrEP), and syringe services programs (SSPs) (Prevent). This analysis aimed to concisely compare NHBS key findings among PWID to EHE goals.
DESIGN/METHODS: Cross-sectional NHBS data were collected from PWID in 2018 ( n = 9786) and 2022 ( n = 6574) in 19 US cities. We compared key findings from 2022 NHBS to specified EHE goals for Diagnose (HIV testing) and Treat (linkage to care, current antiretroviral therapy (ART) use) or 2018 NHBS key findings for Prevent (PrEP and SSP use).
In 2022, 45% of PWID were tested for HIV; 45% of PWID with HIV were linked to care within 1 month of diagnosis, and 79% were currently taking ART; 1% of PWID without HIV used PrEP; and approximately half of all PWID received syringes from an SSP. PrEP and SSP use among PWID have not changed since 2018.
National HIV strategies are not yet adequately reaching PWID. To end the US HIV epidemic, multilevel solutions are needed to tailor interventions for PWID and dismantle barriers to testing, treatment, and prevention. Structural solutions to improve access to basic needs and SSPs may have downstream benefits across the EHE strategies.
国家艾滋病病毒行为监测（NHBS）对包括注射吸毒者（PWID）在内的重点人群进行监测。NHBS数据可用于监测实现国家目标的进展情况，包括终结艾滋病流行（EHE）。EHE策略包括艾滋病病毒检测（诊断）、快速转介至艾滋病病毒治疗（治疗）、增加暴露前预防（PrEP）的可及性以及注射器服务项目（SSP）（预防）。本分析旨在简要比较PWID人群中NHBS的主要发现与EHE目标。
设计/方法：横断面NHBS数据于2018年（n = 9786）和2022年（n = 6574）在美国19个城市的PWID中收集。我们将2022年NHBS的主要发现与诊断（艾滋病病毒检测）和治疗（转介至医疗护理、当前抗逆转录病毒治疗（ART）的使用）的特定EHE目标进行比较，或将2018年NHBS的主要发现与预防（PrEP和SSP的使用）进行比较。
2022年，45%的PWID接受了艾滋病病毒检测；45%感染艾滋病病毒的PWID在诊断后1个月内转介至医疗护理，79%目前正在接受ART治疗；1%未感染艾滋病病毒的PWID使用PrEP；所有PWID中约一半从SSP获得注射器。自2018年以来，PWID中PrEP和SSP的使用情况没有变化。
国家艾滋病病毒策略尚未充分惠及PWID。为终结美国的艾滋病流行，需要采取多层次解决方案，为PWID量身定制干预措施，消除检测、治疗和预防方面的障碍。改善基本需求和SSP可及性的结构性解决方案可能会在整个EHE策略中产生下游效益。
